![LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University](https://www.seventure.fr/wp-content/uploads/2018/10/4__104270789-322x211.jpg)
16 October 2018
LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders
Search
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders